5 Top NASDAQ Biotech Stocks: Array BioPharma Shares Up On Clinical Trial Results

The NASDAQ Biotechnology index (INDEXNASDAQ:NBI)   fell steadlily to the middle of the week, but slowly inched upwards to a high of 3,027.15 on Friday, with the five day trading week up by 1.16 percent.
Last week’s top 5 companies recorded over 20 percent gains for the week. Here is a look at how the companies performed last week.

• Array BioPharma (NASDAQ:ARRY)
• Allied Healthcare Products (NASDAQ:AHPI)
• Ekso Bionics Holdings (NASDAQ:EKSO)
• Aurinia Pharmaceuticals (NASDAQ:AUPH)
• GW Pharmaceuticals (NASDAQ:GWPH)

Array BioPharma

Array BioPharma is focused on cancer treatments, from discovery, development to commercialization. The company has five registration studies currently advancing related to three cancer drugs. Shares of Array Biopharma rose last week when the reported positive results from its melanoma treatment clinical trial.
Array BioPharma gained 84.93 percent over the five day trading period and ended the week at $6.75 per share.

Allied Healthcare Products

Allied Healthcare Products manufactures and markets respiratory products, including respiratory care products, medical gas equipment and emergency medical products. There has been no recent news from the company to explain last week’s rise in share price.
Allied Healthcare gained 53.66 percent over the five day trading period and ended the week at $0.82 per share.

Ekso Bionics Holdings

Ekso Bionics designs, develops and sells wearable bionic human exoskeletons used in healthcare, industrial, military and consumer markets. There has been no recent news from the company to explain last week’s rise in share price.
Ekso Bionics gained 32.39 percent over the five day trading period and ended the week at
$4.70 per share.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is focused on developing its novel therapeutic drug candidate, Voclosporin, for the treatment of lupus nephritis. Shares rose sharply on Friday when the company announced positive results from its AURA-LV phase 2b clinical trial for the assessment of Voclosporin, an immunosuppressant with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus patients.
Aurinia Pharmaceuticals gained 25.42 percent over the five day trading period and ended the week at $3.01 per share.

GW Pharmaceuticals

GW Pharmaceuticals is no stranger to our weekly gainers list, having been on top of the list back in March. The company develops cannabinoid medicines, including Epidiolex®, an oral medicine for the treatment of refractory childhood epilepsies. Shares trended upward steadily throughout the week after the company announced positive results of its second Phase 3 clinical trial of Epidiolex®.
GW Pharmaceuticals gained 23.40 percent over the five day trading period and ended the week at $132.73 per share.
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.